Search

Search Constraints

You searched for: Author/Creator Gabel, Silvy

Search Results

1. [IC‐P‐191]: IN VIVO MAPPING OF TAU DEPOSITION, PERFUSION, AND CORTICAL THINNING IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. (1st July 2017)

2. [O4–04–04]: [18F]AV‐1451 PET IMAGING OF TAU PATHOLOGY PREDICTS WHITE MATTER HYPERINTENSITIES IN HEALTHY AGING, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE: THE NIMROD STUDY. (1st July 2017)

3. [P2–358]: IN VIVO MAPPING OF TAU DEPOSITION, PERFUSION, AND CORTICAL THINNING IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. (1st July 2017)

4. [P4–493]: IN VIVO VISUALIZATION OF [18]F‐THK5351 BINDING IN PRIMARY PROGRESSIVE APHASIA. (1st July 2017)

5. A metabolite‐based machine learning approach to diagnose Alzheimer‐type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. Issue 1 (1st January 2019)

6. Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non‐Alzheimer's disease pathophysiology. Issue 3 (14th June 2022)

7. Comparison of two analytical platforms for blood‐based surrogate biomarkers of amyloid pathology: Biomarkers (non‐neuroimaging) / plasma/serum/urine biomarkers. (7th December 2020)

8. CSF proteomic profiling of mild cognitive impairment individuals with suspected non‐Alzheimer's disease pathophysiology: Developing topics. (7th December 2020)

9. Differential involvement of limbic and paralimbic cortex in episodic memory processing in cognitive aging and neurodegeneration: Neuroimaging / Optimal neuroimaging measures for early detection. (7th December 2020)

10. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Issue 11 (5th September 2019)